U.S. District Court Grants Stay in Case Between SenoRx (SENO) and Hologic (HOLX)
More News related to HOLX
- Hologic to Present at the Morgan Stanley Global Healthcare Unplugged Conference
- Lazard Starts Hologic (HOLX) at Buy
- Matrix USA Rating Changes 8/27
- Hologic (HOLX) Sees Insider Buying from CEO and President.
- Hologic to Present at the Canaccord Adams 28th Annual Global Growth Conference
More News related to SENO
- SenoRx Continues International Expansion Into Five Additional Countries
- SenoRx to Present at 2008 Southern California Investor Conference
- SenoRx and Hologic Agree to Resume Proceedings in Lawsuit
- SenoRx Reports 37.7 Percent Growth in Second Quarter 2008 Revenue; Gross Margins Increase to 61.3 Percent From 57.0 Percent a Year Ago
- SenoRx to Present At the 28th Annual Canaccord Adams Global Growth Conference
SenoRx (Nasdaq: SENO) announced that the United States District Court for the Northern District of California has granted a joint request by Hologic (Nasdaq: HOLX) and SenoRx to stay all proceedings in the case currently pending between the parties, including the Markman claims construction hearing (previously scheduled for June 25, 2008) and trial (previously scheduled to begin on July 14, 2008), for at least sixty days in order to provide the parties time to discuss possible resolution of the matter.
SenoRx, Inc. is a medical device company focused on developing, manufacturing and selling minimally invasive medical devices for the diagnosis of breast cancer.
Related Categories
Corporate NewsStocks Mentioned
+0.63Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
